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Abstract
Renal disease has a high incidence in cats, and some evidence implicates dietary P as well. To investigate this further, two studies in healthy
adult cats were conducted. Study 1 (36 weeks) included forty-eight cats, stratified to control or test diets providing 1·2 or 4·8 g/1000 kcal (4184
kJ) P (0 or approximately 3·6 g/1000 kcal (4184 kJ) inorganic P, Ca:P 1·2, 0·6). Study 2 (29 weeks) included fifty cats, stratified to control or test
diets, providing 1·3 or 3·6 g/1000 kcal (4184 kJ) P (0 or approximately 1·5 g/1000 kcal (4184 kJ) inorganic P, Ca:P 1·2, 0·9). Health markers,
glomerular filtration rate (GFR) and mineral balance were measured regularly, with abdominal ultrasound. Study 1 was halted after 4 weeks as
the test group GFR reduced by 0·4 (95% CI 0·3, 0·5)ml/min per kg, and ultrasound revealed changes in renal echogenicity. In study 2, at week
28, no change in mean GFR was observed (P> 0·05); however, altered renal echogenicity was detected in 36% of test cats. In agreement with
previous studies, feeding a diet with Ca:P <1·0, a high total and inorganic P inclusion resulted in loss of renal function and changes in
echogenicity suggestive of renal pathology. Feeding a diet containing lower total and inorganic P with Ca:P close to 1·0 led to more subtle
structural changes in a third of test cats; however, nephrolithiasis occurred in both diet groups, complicating data interpretation. We conclude
that the no observed adverse effects level for total dietary P in adult cats is lower than 3·6 g/1000 kcal (4184 kJ), however the effect of inorganic
P sources and Ca:P require further investigation.
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Chronic kidney disease (CKD) has a high prevalence in domestic
cats, with approximately 33% of those over the age of 12 years
being affected(1). CKD is defined as a sustained decrease in renal
function over at least 3 months and is an important cause of
morbidity and mortality in the cat population. Both congenital
and acquired disorders can lead to the development of CKD
and acute kidney damage owing to urinary obstruction,
nephrotoxins and pyelonephritis, or ischaemic injury can also
progress to chronic disease(2). Although dietary P is essential for
life, unrestricted P intake has been associated with the pro-
gression of existing renal disease(2,3). There is, however, little
evidence to indicate adverse effects of high P intake in healthy
adult cats. For this reason, there is currently no safe upper limit
for feline dietary P cited in nutritional guidelines set out by the
US National Research Council (NRC), European Pet Food
Industry Federation or Association of American Feed Control
Officials (AAFCO)(4–6).
The first study to suggest a link between high dietary P and
reduced renal function in healthy adult cats was reported by
Pastoor et al.(7). To evaluate the effects of high P intake, the
authors fed a purified test diet containing 3·6 g P/1000 kcal
(4184 kJ) with a Ca:P ratio of 0·3 for 4 weeks. A small, but
significant, reduction in endogenous creatinine clearance and a
slight decrease in plasma P were reported in cats offered the test
diet compared with those offered P at a level of 2·3 g/1000 kcal
(4184 kJ) or below(7). A neutral P balance was observed owing
to an increase in both urinary and faecal P excretion when
higher levels were fed, suggesting that P levels were regulated
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and excess P excreted rather than retained. These authors
recommended that high dietary P levels should be discouraged
owing to the associated reduction in plasma P concentrations
and creatinine clearance. Subsequently, Dobenecker et al.(8)
offered thirteen healthy adult cats a diet comparable to a home-
prepared formulation with a total P of 3·0 g/1000 kcal (4184 kJ) with
approximately 2·0g/1000 kcal (4184 kJ) supplemented as cal-
cium monophosphate and sodium dihydrogen phosphate
(SDHP) with a Ca:P of 0·4. After 29d of feeding, in agreement with
the findings of Pastoor et al.(7), glucosuria and microalbuminuria
were observed, creatinine clearance significantly decreased and
blood urea nitrogen content increased(8).
It has been suggested previously in several species that P
homoeostasis is not only influenced by total dietary P content
and the Ca:P, but also by the source of P(9–11). Dietary P pro-
vided by organic raw materials (e.g. poultry meal or meat and
bone meal) has been shown to be less bioavailable than that
arising from added inorganic sources (e.g. P containing mono
and dibasic Na salts)(7,12). P-based additives are widely used in
commercial food manufacturing not only to supplement essen-
tial P but also to serve a number of processing functions including pH
stabilisation, metal cation sequestration, emulsification, leavening,
hydration and as antibacterials(13). This difference in bioavail-
ability is probably because of in vivo binding of organic P to
proteins and intra-cellular signalling molecules, while inorganic
P salts are readily disassociated and absorbed(10). Data from rats
fed high-phosphate diets supplemented with monophosphate
or polyphosphate salts has indicated that the development of
nephrocalcinosis and diminished kidney function is more severe
when polyphosphate salts as compared with monophosphate salts
are fed(11). In cats, Finco et al.(12) compared a diet with 100% P
from an organic source (total P content
2·7g/1000kcal (4184 kJ), Ca:P 1·6) with a diet containing a similar
total P (3·3g/1000kcal (4184 kJ) and Ca:P 1·4), but with 63·5% P
from neutral monobasic/dibasic sodium phosphate. These authors
noted a greater percentage recovery of P in the urine when the
high-inorganic P diet was fed compared with the organic P diet
(34·9% compared with 14·7%). However, these findings may have
been influenced by the higher Na level present in the inorganic P
diet, which is known to increase P absorption by stimulating Na+-
dependent uptake of phosphate(14).
Together, these studies highlight a possible risk of changes in
renal function when healthy adult cats are fed diets containing
levels of P in excess of 3·0 g/1000 kcal (4184 kJ), or when high
levels of P from inorganic sources are included in diets. How-
ever, the available evidence is not conclusive and the published
data do not determine whether the reported changes exceeded
normal reference ranges or have clinical relevance. The diets
used in these studies do not represent commercially relevant
formats being either purified(7) or representative of ‘home-
prepared’ diets(8). Therefore, to elucidate the effects of dietary P
in cats, a long-term feeding study was initiated with the objec-
tive of evaluating the health effects of an extruded dry format
diet containing total and inorganic P (in the form of SDHP), at
levels higher than previously reported, but possible in some
commercial pet foods(15). This study observed adverse changes in
markers of renal health after 4 weeks of feeding and was termi-
nated at this stage. We hypothesised that the adverse effects may
have been due to the inclusion of highly available inorganic
SDHP. Subsequently, a second 29-week study was initiated in
which an extruded dry format diet with a lower inclusion of
inorganic SDHP and a total P level equivalent to that previously
reported by Pastoor et al.(7) was fed, in an attempt to identify a
level of dietary P inclusion resulting in no observed adverse effects
level (NOAEL) in adult cats.
Methods
Study design
This work was approved by the WALTHAM Animal Welfare and
Ethical Review Body and conducted under the authority of the
Animals (Scientific Procedures) Act 1986.
Study 1. In a parallel design, forty-eight healthy neutered adult
cats (twenty-three males and twenty-five females) aged between
1·7 and 9·1 years at the start of the study were stratified into two
study groups and offered one of two extruded dry format diets,
differing in P content and Ca:P. Throughout an initial baseline
period of 20 weeks, all cats were offered a control diet 74%
lower in P than the test (Table 1), and baseline measurements
were made within the final 4 weeks. Subsequently, test cats were
offered a high-P test diet (Table 1), whereas the control cats
remained on the control diet. After 4 weeks, measurements were
repeated for both groups. Following review of these data, the
study was terminated and the test cats returned to the control diet
in week 6.
Study 2. In a parallel design, fifty healthy neutered adult cats
(twenty-nine males and twenty-one females) aged between 1·4
and 7·8 years at the start of the study were stratified into two
study groups and offered one of two extruded diets, differing in
P content and Ca:P. Throughout an initial baseline period of
10 weeks, all cats were offered a lower P control diet (Table 1)
and baseline measurements were made towards the end of this
phase. Subsequently, test cats were offered a moderate P test
diet (Table 1), whereas the control cats remained on the lower P
control diet. Measurements were repeated after 2, 4, 8, 12, 20
and 28 weeks.
Animals and housing
Study 1 included forty-eight healthy neutered adult cats strati-
fied into two study groups balancing energy intake, body
weight (BW) and age. The control group was made up of
twelve males and twelve females with a median starting age of
4·7 (1·7–8·1) years and the test of eleven males and thirteen
females with a median starting age of 4·3 (1·7–9·1) years. Before
selection, cats were health-screened by assessment of plasma
biochemistry, haematology, urinary health parameters and
abdominal ultrasound. Those with findings outside of normal
range or considered abnormal by the site veterinarian were
excluded, as were cats identified as having crystalluria, pre-
existing uroliths, renoliths or abnormal changes in renal size or
echogenicity, as determined by a diplomate of the European
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College of Veterinary Diagnostic Imaging (H. R.). Study 2
included fifty healthy neutered adult cats stratified into two
study groups balancing energy intake, BW and age. The control
group consisted of thirteen males and twelve females with a
median starting age of 5·4 (1·4–7·7) years, and the test group
was made up of fifteen males and ten females with a mean
starting age of 4·6 (1·4–7·7) years. Before selection, cats were
health-screened by applying the same criteria as for study 1. All
cats were housed at the WALTHAM Centre for Pet Nutrition
in social rooms, except during feeding or urine and faecal
collection periods; to facilitate sample collection, they were
individually housed in lodges. Cats received two 30-min meals
(50% of maintenance energy requirement) per day, a pattern
they were habituated to. Throughout the study, diets were
offered in amounts to maintain an ideal body condition score
according to the WALTHAM Size, Health and Physical Evalua-
tion Guide(16). Deionised water was freely available at all times.
Initial energy requirements were determined using observed
energy intakes over the preceding 2 months.
Diets
In study 1, single batches of two extruded dry format experi-
mental diets were specifically formulated for this study and
manufactured (Royal Canin) using the same core recipe and
raw materials, but with differing levels of P.
Both diets were composed of similar quantities of pork meal,
pork fat and rind, poultry fat, soya and fish oils, yeast, beet pulp,
ground rice, cellulose fibre, maize flour and gluten, potassium
chloride, potassium citrate, sodium chloride, magnesium oxide,
calcium bicarbonate (study 1), a vitamin premix, anticaking agent
and flavourings. The control diet contained 1·2g P/1000kcal
(4184 kJ) (all provided from organic raw materials) with 1·3 g Ca/
1000kcal (4184 kJ) (Ca:P 1·1) and the higher P test diet contained
4·8gP/1000kcal (4184 kJ) (approximately 3·6g/1000kcal (4184 kJ)
from inorganic sources) with 2·8g Ca/1000kcal (4184 kJ) (Ca:P 0·6
(Table 1). The additional Ca and P in the test diet were provided
by inorganic calcium carbonate (2·6%) and SDHP (5·2%).
However, to achieve a Ca:P of 0·6, the test diet was supple-
mented before feeding with calcium citrate malate (Metabolics
Ltd) at a dose of 200mg Ca/1000 kcal (4184 kJ). Diet analysis
confirmed that the nutritional composition of both diets met NRC
(2006) adult cat recommendations for all nutrients except choline
in the test diet, which was supplemented with 118mg/1000kcal
(4184 kJ) choline chloride (Metabolics Ltd) to ensure compliance
(online Supplementary Table S1).
In study 2, single batches of two extruded dry format
experimental diets were specifically formulated for this study
and manufactured (Royal Canin) using the same core recipe
used in study 1 and the same raw materials for both diets
with additional pork meal added to the test diet. Control diet
contained 1·3 g P/1000 kcal (4184 kJ) (all provided from organic
raw materials) with 1·6 g Ca/1000 kcal (4184 kJ) (Ca:P 1·2) and
the moderate P test diet contained 3·6 g P/1000 kcal (4184 kJ)
(approximately 1·5 g/1000 kcal (4184 kJ) from inorganic sour-
ces) with 3·3 g Ca/1000 kcal (4184 kJ) (Ca:P 0·9) (Table 1). The
additional Ca and P in the test diet were provided through
organic sources: bone ash from protein meal supplemented
with inorganic calcium carbonate (1·5%) and SDHP (2·2%).
Both diets met NRC (2006) recommendations for adult cats
(online Supplementary Table S1).
All diets were produced through a standard extrusion process
commonly used in the pet food industry(17). Diet ingredients
were mixed before being extruded and kibbled under identical
processing conditions in a single-screw extruder (Royal Canin). All
nutritional chemical analyses were carried out using Association of
Official Agricultural Chemists (AOAC) procedures at Eurofins Ltd.
Measures
Intake was recorded on an individual basis as mass (g) of diet
offered minus mass (g) of diet refused. BW was recorded weekly
Table 1. Diet composition*
Diet
Study 1 control
(g/1000 kcal
(4184 kJ))
Study 1 control
(g/100 g)
Study 1 test (g/1000 kcal
(4184 kJ))
Study 1
test
(g/100 g)
Study 2 control
(g/1000 kcal
(4184 kJ))
Study 2
control
(g/100 g)
Study 2 test
(g/1000 kcal
(4184 kJ))
Study 2
test
(g/100 g)
P 1·23 0·52 4·78 1·93 1·33 0·56 3·59 1·49
Ca 1·33 0·56 2·80† 1·13† 1·58 0·65 3·34 1·39
Ca:P 1·08 1·08 0·59 0·59 1·19 1·17 0·93 0·93
Na 3·11 1·31 3·33 1·35 1·50 0·62 1·35 0·56
Mg 0·40 0·17 0·18 0·07 0·25 0·10 0·28 0·12
Chloride 4·63 1·95 1·65 0·67 3·27 1·36 1·39 0·59
Vitamin
D3‡
254·22 106·84 182·80 73·52 301·37 125·40 183·45 76·08
Protein 68·13 28·63 61·13 24·68 61·54 25·61 64·27 26·63
Fat 39·32 16·53 39·88 16·10 39·76 16·54 42·61 17·50
Ash 19·29 8·11 28·07 11·33 15·96 6·64 21·53 8·87
Crude fibre 5·50 10·00 5·20 10·15 7·34 3·06 7·49 3·15
Moisture 12·52 0·00 14·69 0·00 12·92 0·00 12·14 0·00
PME§ 420·27 403·76 416·08 412·00
PME, predicted metabolisable energy.
* Diet analysis g/1000 kcal (4184 kJ) or g/100g DM.
† Value after supplementation of Ca at 200mg/1000 kcal (4184 kJ).
‡ International units IU/1000 kcal (4184 kJ) or IU/100 g.
§ Calculated by proximate analysis to PME kcal/100g according to LaFlamme(75).
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(in kg) on a standard scale (FB 34 3DE P top-pan balance;
Sartorius).
Mineral balance. At baseline and after 4, 12, 20 and 28 weeks
of feeding, five day total faeces and urine collections were
carried out to determine mineral apparent digestibility. Samples
were analysed for Ca using flame photometry and P using
spectrophotometry at the Royal Canin SAS European Regional
Laboratory. Faeces were stored frozen at –20°C in a sealed
container until processing. Each pooled 5-d faecal collection
was weighed and then freeze-dried (VirTis Benchtop BTP9ES
Freeze Dryer, Biopharma Process Systems). Once dried, the faeces
was reweighed and manually homogenised in a mortar and pestle;
any foreign material was removed and weighed separately. A 20-g
aliquot of the homogenate was analysed for moisture, crude fibre
and ash content, according to methods described in the Journal
Official de l’Union Européenne procedures(18); fat content was
determined by acid hydrolysis followed by diethyl ether extraction
and crude protein calculated from total N content by combustion
using the Dumas principle according to Association Française de
Normalisation (AFNOR ISO 16634-1:2008 November 2008). P
content was determined via spectral photometry and Ca and Mg
by flame photometry according to AFNOR methodology at Invivo
Labs Chateau-Thierry. Apparent mineral digestibility (%) was cal-
culated for Ca and P to represent the fraction of the minerals that
were retained from the diet rather than being excreted in the
faeces using the following formula:
Apparent digestibility %ð Þ= ððintake faecal excretionÞ = intakeÞ
´ 100:
Mineral balance (g) was also calculated for P and Ca as:
Total mineral balance gð Þ
= intake faecal excretion + urinary excretionð Þ
Urine mineral content and relative super saturation (RSS).
All urine excreted over a 3-d (study 1) or 5-d (study 2) period was
collected and urine pH assessed twice daily. The method for
urine RSS analysis has been previously described(19). Samples
were analysed for oxalate, citrate, pyrophosphate, K, Ca, Na,
ammonium, chloride, sulphate and phosphate via HPLC. The
concentrations of minerals were then analysed by SUPERSAT soft-
ware(19) to calculate the RSS (activity product/solubility product) for
struvite (magnesium ammonium phosphate (MAP)), calcium oxa-
late (CaOx) and brushite (study 2 only). The urine P and Ca content
were determined via spectral photometry and flame photometry,
respectively, according to AFNOR methodology at Invivo Labs
Chateau-Thierry and used for calculation of the urinary fractional
excretion of these minerals.
Urinalysis. At baseline and after 4 weeks of feeding (study 1) or
baseline and after 4, 12, 20 and 28 weeks of feeding (study 2), a
5-ml freshly voided urine sample was collected from each cat,
and creatinine, microalbumin, pH, urine-specific gravity, glu-
cose, pH and urine protein creatinine ratio were measured
(InSight MS-11 and MS-2 Vet urine strips; Woodley Equipment
Company Ltd) within 30min. Specific gravity was also deter-
mined using a refractometer (Sinotech RHCN-200ATC; Sino-
tech) and urine albumin and creatinine measured using the
Beckman Coulter microalbumin (OSR6167) and creatinine
(OSR6178) assays for the Olympus AU480 biochemistry
analyser (Olympus Europe GmbH). The urine albumin:
creatinine ratio (UACR) was then calculated for each sample.
Blood-based measures. At baseline and every 2–8 weeks
thereafter, morning fasted (>12h) blood samples were collected
for the measurement of standard biochemistry and haematology,
ionised Ca (iCa), vitamin D metabolites, TAG, markers of bone
turn-over, serum crosslaps (CTx) and bone-specific alkaline
phosphatase (BAP), parathyroid hormone (PTH) and fibroblast
growth factor 23 (FGF23). EDTA-treated blood was used to
measure standard haematology parameters (leucocyte and
erythrocyte counts, Hb concentration, haematocrit, platelet
count, mean corpuscular volume, mean corpuscular Hb, number
and percentage of lymphocytes, monocytes and granulocytes)
via a Mythic 18 cell counter (Orphee).
Lithium-heparinised plasma was analysed to quantify standard
biochemistry parameters (total protein, albumin, phosphate,
alkaline phosphatase (ALP), alanine transaminase, aspartate amino-
transferase, Ca, cholesterol, urea, creatinine, TAG and glucose). In
study 1, this was carried out in-house using an AU480 (Olympus)
analyser. In study 2, heparinised serum was sent to an external
laboratory (IDEXX Laboratories) for biochemical analysis as in
study 1 with the addition of symmetric dimethylarginine
(SDMA) measurement. Serum was collected for the measure-
ment of markers of bone turnover: BAP and CTx using the BAP
MicroVue™ Quidel ELISA (TECO Medical Group) and CartiLaps®
ELISA (Immunodiagnostic Systems Ltd), both according to the
manufacturer’s instructions. In the Department of Comparative
and Biomedical Sciences, Royal Veterinary College, London,
EDTA plasma was analysed to quantify intact plasma FGF23
concentrations using a sandwich ELISA (Kainos Laboratories Inc.)
as detailed by Geddes et al.(20) and PTH concentrations by a total
intact PTH immunoradiometric assay (Scantibodies Laboratory,
Inc.) previously validated for use with feline samples(21). Serum
was also collected for the measurement of the vitamin D meta-
bolites 25-hydroxyvitamin D (25(OH)D) and 24,25-dihydrox-
yvitamin D (24,25(OH)2D) by liquid chromatography (LC)/MS–MS
(Agilent) using a modified method described by Aronov et al.(22).
Serum was also collected for the measurement of the vitamin D
metabolites at the Bioanalytical Facility at the University of East
Anglia, Norwich, UK. Total 25(OH)D, total 24,25(OH)2D and the
epimer C3-Epi-25(OH)D3 were measured by LC/MS–MS (per-
formed using a Micromass Quattro Ultima Pt Mass Spectrometer
(Waters Corp.). Total serum 1,25-dihydroxyvitamin D (1,25
(OH)2D) levels were measured using an EIA Kit (IDS Ltd). iCa
analysis was conducted using heparinised whole blood in a Stat
Profile Prime Critical Care analyser (Nova Biomedical).
Plasma and serum calcium–phosphorus (CaP) product
(mmol2/l2) was calculated by multiplying plasma total Ca and
inorganic P concentrations in mmol/l.
Renal measures. In study 1, at baseline and 5 weeks after diet
change, and in study 2 at baseline, 5, 13, 21 and 29 weeks after
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diet change, iohexol clearance tests were carried out as an
estimate of glomerular filtration rate (GFR) using the method
described by Finch et al.(23). Briefly, for topical anaesthesia, 2ml
of EMLA cream (2·5% lidocaine, 2·5% prilocaine; AstraZeneca)
was applied to the skin over the cephalic veins and covered for
1 h before removal and aseptic preparation of the area with
chlorhexidine gluconate. The cephalic vein was raised by
pressure to the dorsal aspect of the foreleg and a catheter was
inserted into the vein before flushing with 0·5ml of heparinised
saline (100 IU/ml of heparin in 0·9% saline; Wockhardt UK Ltd).
A discard volume of 300 µl was removed from the catheter and
647mg/kg iohexol (Omnipaque 300; Amersham Health) was
administered over a 3-min period, followed by a heparinised
saline flush. The completion of the injection represented time
zero. Blood samples of 1ml volume were collected via a
cephalic catheter into serum tubes at 2, 3 and 4 h post infusion.
Iohexol concentration in the serum of each cat at each time
point was analysed using high-performance capillary electro-
phoresis (undertaken in the laboratories of deltaDOT Ltd and
London BioScience Innovation Centre). Weight-adjusted clear-
ance (in ml/kg per min) was calculated by the slope of the
concentration gradient.
The fractional excretion of P (FEP) and Ca (FECa) was cal-
culated as the percentage filtered by the glomerulus excreted
into the urine, expressed as a ratio to creatinine clearance as
below:
% FE
=
urinary concentration of ½X ´ circulating creatinine concentration
urinary concentration of creatinine ´ circulating ½X concentration
´ 100
Imaging: at baseline and at the end of both studies, general
physical health examinations, whole-body radiographs and
abdominal ultrasound scans were carried out to detect soft tissue
mineralisation, urolithiasis or other pathologies. Radiographs of the
abdomen were taken in ventrodorsal and right lateral recumbency,
those of the thoraxwere taken in right lateral recumbency (AGFACR
30-X, exposure range 46–64kV, 2·36–4·73mAs) and full abdominal
ultrasound scans (GE Logiq-E with a linear probe 307 12L-RS, 5–-
13mHz, 47mm footprint) were performed, with the cats under
sedation (induced through administration of 0·3mg/kg butorphanol
0·025mg/kg dexmedetomidine and reversed with 0·075mg/kg ati-
pamazole). All scans and interpretation of the radiographs were
carried out by a diplomate of the European College of Veterinary
Diagnostic Imaging (H. R.) whowas blinded to the dietary grouping.
Post-mortem and histological investigations. In study 2, one
cat from the test group presenting at week 27 with acute renal
failure did not respond to treatment and was euthanised fol-
lowing a pre-defined clinical management pathway. Post-
mortem and histological investigations, including Von Kossa
staining to visualise Ca mineralisation(24), were carried out by a
diplomate of the European College of Veterinary Pathologists at
the Animal Health Trust, Diagnostic Laboratory Services, Lan-
wades Park, Kentford, Newmarket, Suffolk, UK.
Statistical power. Both studies were powered according to
the primary response variable GFR (iohexol clearance ml/min
per kg), by simulation using baseline values from study 1 to
estimate variance. To detect a change in distribution where 10%
of cats had values <0·92ml/min per kg, with approximately 80%
power and using a test level of 5%, twenty cats were required
per diet group. An additional 4–5 cats/group were used in study
1 and an extra five in study 2, to allow for potential drop-out.
Statistical analysis. For each measure, linear mixed model,
restricted maximum likelihood (REML) analyses were performed
to estimate variance parameters allowing for repeated measures
on each subject over time. Specifically, a random effect of cat and
categorical fixed effects of diet, week and their interaction were
used. For some measures, data were missing due to samples not
taken or undue assay variability; however, the REML method of
analysis was used to account for this and assumed these values
were missing at random. The model made use of the incomplete
data so that these did not bias the estimates. Distributional
assumptions were checked to ensure robustness of the statistical
models by performing residual checks (e.g. for randomness and
constant variance). Residuals were found to have increasing
variability for a number of measures, and these were log10
transformed before analyses.
GFR was the primary measure; however, an overall test level of
5% was also applied for all other supportive measures regarded
as secondary. Planned comparisons were calculated between diet
groups at baseline and within and between each diet groups from
baseline to subsequent time points. For each measure, family-
wise adjustments were made for the number of comparisons to
maintain an overall test level at 5%. Accordingly, mean, difference
in mean or fold change of mean (where log10 transformation was
necessary) are reported with 95% family wise CI. Analyses were
performed in R version 3.3.3(25) using libraries ‘lme4’ for linear
mixed effects models(26), ‘multcomp’ for simultaneous inference
of planned contrasts(27) and ‘ggplot’(28) for figures.
Results
For behavioural reasons, occasional missed or partial samples
occurred and sample numbers are presented in the relevant
figures and tables.
Study 1
Intake and body weight. Increased incidence of vomiting was
noted in the test group from week 1 of feeding and average daily
energy intake (per kg BW) reduced significantly (P< 0·001) in
the test group from 43·14 (95% CI 39·23, 47·05) to 37·56 (95% CI
33·65, 41·47) kcal/kg BW (180·5 (95% CI 164·1, 196·9) to 157·1
(95% CI 140·8, 173·5) kJ/kg BW) and this change was sig-
nificantly (P< 0·001) different from the control group, which
remained stable at 42·87 (95% CI 38·96, 46·78) kcal/kg baseline
and 43·93 (95% CI 40·02, 47·84) kcal/kg BW (179·4 (95% CI
163·0, 195·78) kJ/kg baseline and 183·8 (95% CI 167·4, 200·2) kJ/
kg BW) at week 4 (online Supplementary Table S2). Corre-
spondingly, the mean BW in the test group reduced significantly
(P< 0·001) from baseline, whereas that of the control group did
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not change (P> 0·05) and this change was significantly
(P< 0·001) higher in the test group at week 4 (online Supple-
mentary Table S2). When transferred to the test diet, mean P
intake in the test group increased significantly (P< 0·001) to 0·18
(0·17, 0·19) g/kg BW compared with 0·06 (0·04, 0·07) g/kg BW in
the control (online Supplementary Table S2). Mean Ca intake
was also observed to increase significantly (P< 0·001) in the test
group to 0·13 (0·12, 0·14) g/kg BW, compared with 0·06 (0·05,
0·07) g/kg BW in the control.
Mineral apparent digestibility and balance. Urinary and
faecal P excretion in the test group increased significantly
(P< 0·001) from baseline and in comparison with the control
group (Fig. 1(a)). Urinary excretion of Ca did not change from
baseline in either group; however, faecal excretion increased
significantly (P< 0·001) in the test group and was significantly
different (P< 0·001) from the change in the control (Fig. 1(b)).
Apparent digestibility (dietary intake minus faecal losses) of
dietary P was not significantly (P> 0·05) different between the
control and test groups at baseline: 37·83 (32·34, 43·33) and
38·02 (32·41, 43·63)% respectively. After 4 weeks, P apparent
digestibility in the test group increased by 11·28 (3·70, 18·86)%
and this change was significantly (P= 0·003) different from that in
the control. In the test group, Ca apparent digestibility reduced
significantly (P= 0·001) from baseline over the feeding period,
but this change was not significantly different (P= 0·139) from
the change in the control group.
Total P and Ca balance were not significantly different
between diet groups at baseline (Fig. 1(a) and (b)). After the
feeding period, P balance was not significantly different from
baseline (P= 0·211) (Fig. 1(c)), whereas total Ca balance reduced
(P< 0·001) by 0·46 (0·16, 0·76) g to become negative in the test
group at week 4 and this change was significantly different from
that of the control group (Fig. 1(d)).
Glomerular filtration rate. No difference between groups in
GFR was observed at baseline (Fig. 2). Although GFR reduced
significantly (P< 0·05) in both groups over the feeding period, a
significantly greater reduction (P< 0·001) was observed in the
test group compared with the control by 0·26 (0·11, 0·41)ml/min
per kg (Fig. 2).
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Fig. 1. Study 1, (a) daily faecal and urinary phosphorus excretion (g/kg) n 23–24, (b) daily faecal and urinary calcium excretion (g/kg) n 23–24, (c) phosphorus balance
(daily intake minus total daily faecal and urinary excretion in g), n 24 and (d) calcium balance (g), n 24, by study week and diet. Individual cat data are shown as small
symbols and means as large symbols with 95% CI. * Significant between diet difference in change from baseline (P< 0·05). Total mineral balance (g) calculated as
intake– (faecal excretion + urinary excretion). (a, b) , Urine – control; , urine – test; , faeces – control; , faeces – test. (c, d) , Control; , test.
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Blood biochemistry. At baseline, no significant differences
were observed between diet groups in any parameter except
iCa, which was significantly (P= 0·035) higher in the control
group by 0·021 (0·001, 0·041)mmol/l (Table 2). However, over
the feeding period, control group iCa levels reduced to those
of the test group, which did not change (Table 2). After
4 weeks of feeding, significant changes were observed in a
number of parameters (Table 2). Plasma creatinine increased
significantly in the test group by 24·95 (24·38, 25·52) μmol/l
(Fig. 3(a)). In the test group, plasma urea increased sig-
nificantly (P< 0·050) by 1·38 (1·33, 1·44)mmol/l, whereas
albumin levels decreased significantly (P< 0·050) by 2·08
(2·05, 2·11) g/l (Fig. 3(b)). Plasma ALP concentration also
increased significantly in the test group by 0·10 (0·09, 0·12)
µkat/l (Table 2). No significant between group difference was
observed in plasma total Ca levels, although those of the
control group reduced significantly (P= 0·020) (Fig. 3(c)).
Plasma inorganic P concentration decreased significantly
(P< 0·001) in the test but not the control group over the
feeding period by 0·40 (0·39, 0·41)mmol/l (Fig. 3(d)). The
calculated plasma CaP product was not significantly different
between groups at baseline (Table 2); however, after 4 weeks
of feeding the test group CaP had reduced significantly
(P< 0·001) from 3·13 (2·88, 3·40) to 2·12 (1·97, 2·29) mmol2/l2,
and this change was significantly (P< 0·001) different from the
control group, which remained unchanged (Table 2). Addi-
tional blood biochemistry values can be seen in online Sup-
plementary Table S3.
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Fig. 2. Study 1, glomerular filtration rate (GFR) determined by iohexol clearance
(ml/min per kg) by study week and diet. Individual cat data are shown as small
symbols and means as large symbols with 95% CI, n 23–24. * Significant
difference inGFR relative to baseline between diets (P<0·05). , Control; , test.
Table 2. Study 1 selected blood biochemistry, markers of bone metabolism and vitamin D metabolites
(Mean values and 95% confidence intervals)
Control Test
Mean 95% CI Mean 95% CI P
Albumin (g/l) n 24 n 24
Baseline 33·55a 32·57, 34·52 33·11a 32·13, 34·08
Week 4 32·44* 31·46, 33·43 31·03* 30·09, 31·97 0·005
ALP (µkat/l) n 24 n 24
Baseline 0·45a 0·37, 0·54 0·50a 0·41, 0·60
Week 4 0·42 0·34, 0·51 0·60* 0·50, 0·73 <0·001
Ionised Ca (mmol/l) n 24 n 24
Baseline 1·27a 1·25, 1·28 1·24b 1·23, 1·26
Week 4 1·24a* 1·22, 1·25 1·24a 1·22, 1·25 0·007
CaP (mmol2/l2) n 24 n 24
Baseline 3·10a 2·85, 3·37 3·13a 2·88, 3·40
Week 4 2·90 2·66, 3·16 2·13* 1.97, 2.29 <0·001
BAP (U/l) n 23–24 n 23–24
Baseline 6·34a 4·79, 8·39 7·47a 5·68, 9·83
Week 4 6·80 5·14, 9·00 10·41* 7·91, 13·69 <0·001
CTx (ng/ml) n 23–24 n 23–24
Baseline 0·65a 0·50, 0·83 0·84a 0·66, 1·08
Week 4 0·71* 0·55, 0·92 1·03* 0·81, 1·33 0·059
Total 25(OH)D (nmol/l) n 23–24 n 23–24
Baseline 131·60a 116·48, 148·67 138·36a 122·47, 156·31
Week 4 144·20* 127·72, 162·79 115·36* 102·18, 130·24 <0·001
Total 24,25(OH)2D (nmol/l) n 23–24 n 23–24
Baseline 28·52a 23·80, 34·17 27·68a 23·10, 33·16
Week 4 25·06 20·95, 29·97 27·12 22·68, 32·43 0·446
C3-Epi-25(OH)D3 (nmol/l) n 23–24 n 23–24
Baseline 26·24a 22·78, 30·23 27·62a 23·98, 31·81
Week 4 31·94* 27·81, 36·69 24·93 21·70, 28·63 0·007
1,25(OH)2D (pmol/l) n 23–24 n 23–24
Baseline 30·82a 24·48, 38·80 33·06a 26·26, 41·62
Week 4 33·16 26·42, 41·62 27·68 22·05, 34·74 0·092
ALP, alkaline phosphatase; CaP, plasma Ca–P product; BAP, bone-specific alkaline phosphatase; CTx, serum crosslaps; 25(OH)D, 25-hydroxyvitamin D; 24,25(OH)2D, 24,25-
dihydroxyvitamin D; 1,25(OH)2D, 1,25-dihydroxyvitamin D.
a,b Mean values within a row with unlike superscript letters were significantly different between test and control at baseline (P<0·05).
* A significant difference from baseline within group (P<0·05). P-value provides a comparison of the change from baseline at week 4, between test and control diet groups.
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Vitamin D metabolites. In the test group, total 25(OH)D
concentrations fell significantly (P< 0·05) from 138·36 (122·47,
156·31) nmol/l at baseline to 115·36 (102·18, 130·24) nmol/l at
week 4 (Table 2). No significant (P< 0·05) changes were
observed in levels of serum total 24,25(OH)2D over the 4-week
feeding period (Table 2). Serum levels of C3-Epi-25(OH)D3
were not significantly different (P> 0·05) between groups at
baseline, but after 4 weeks of feeding had increased sig-
nificantly (P= 0·01) in the control group, whereas no change
was observed in the test group (Table 2). No significant changes
in serum 1,25(OH)2D were observed over the 4-week feeding
period (Table 2).
Regulatory hormones and markers of bone turnover. Over
the 4-week feeding period, levels of FGF23 increased sig-
nificantly (P< 0·001) in the test group by 5·27 (4·14, 6·71)-fold
(Fig. 4(a)). PTH also increased significantly in both diet groups;
however, in the test group this increase was significantly
(P= 0·01) greater by 4·15 (3·41, 5·06) pg/ml (Fig. 4(b)).
BAP concentrations increased in the test group by 1·39 (1·29,
1·50)-fold, whereas those of the control group did not change
(Table 2) and the difference in change from baseline between
diets was significant (P< 0·001). Serum levels of CTx increased
in both the control and test groups by 1·11 (1·02, 1·19)-fold and
1·23 (1·14, 1·32)-fold, respectively; therefore, the difference in
change between groups did not meet the level of significance
(P> 0·05) (Table 2).
Haematology. A total of five parameters were observed to
change significantly over the feeding period. Mean corpuscular
volume and mean corpuscular Hb reduced in both diet groups,
although this was significantly greater (P< 0·05) in the test
group (online Supplementary Table S4). Red cell distribution
width and mean platelet volume both increased significantly
in the test group, but not in the control (online Supplementary
Table S4), whereas platelet distribution width reduced sig-
nificantly only in the test group (online Supplementary
Table S4).
Urinalysis. Although total daily urine volume increased sig-
nificantly (P= 0·007) in the test group over the feeding period,
no significant between diet difference in change from base-
line was observed (Table 3). Urine specific gravity was
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Fig. 3. Study 1, (a) serum creatinine (µmol/l) and (b) serum urea (mmol/l), (c) serum calcium (mmol/l), (d) serum inorganic phosphorus (mmol/l) by study week and
diet. Individual cat data are shown as small symbols and means as large symbols with 95% CI, n 24. * Significant between diet difference in change from baseline
(P< 0·05). , Control; , test.
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significantly lower in the test group compared with the con-
trol group at baseline (P= 0·04), but increased significantly
(P< 0·05) by week 4 and no significant between diet differ-
ence in change from baseline was observed (Table 3). How-
ever, urine relative supersaturation for CaOx and MAP
decreased significantly in the test group by 1·73 (1·38, 2·17)
and 2·26 (1·39, 3·69)-fold, respectively (Table 3). Urine
microalbumin levels increased significantly (P< 0·05) in the
test cats (Table 3) as did UACR from 1·69 (1·07, 2·67) to 11·70
(7·41, 18·48)mg/g (Fig. 5).
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Fig. 4. Study 1, (a) serum fibroblast growth factor 23 (FGF23, pg/ml), n 23–24 and (b) parathyroid hormone (PTH, pg/ml), n 23–24, by study week and diet. Individual cat
data are shown as small symbols and means as large symbols with 95% CI. * Significant between diet difference in change from baseline (P<0·05). , Control; , test.
Table 3. Study 1 urine analysis
(Mean values and 95% confidence intervals)
Control Test
Mean 95% CI Mean 95% CI P
Daily total urine vol. (ml) n 24 n 24
Baseline 65·95a 55·14, 76·75 58·67a 47·87, 69·47
Week 4 68·60 57·80, 79·41 70·76* 59·96, 81·56 0·252
Microalbumin (mg/l) n 24 n 24
Baseline 4·79a 3·35, 6·83 3·59a 2·52, 5·12
Week 4 5·41 3·80, 7·72 24·97* 17·51, 35·62 <0·001
Urinary creatinine (mmol/l) n 24 n 24
Baseline 24·08a 21·96, 26·19 22·60a 20·48, 24·71
Week 4 20·76* 18·65, 22·88 19·49* 17·38, 21·61 0·992
Specific gravity n 24 n 24
Baseline 1·04a 1·04, 1·04 1·03b 1·03, 1·04
Week 4 1·04 1·04, 1·04 1·04* 1·03, 1·04 0·358
RSS CaOx n 24 n 24
Baseline 1·82a 1·51, 2·21 2·03a 1·68, 2·46
Week 4 1·66 1·37, 2·02 1·07* 0·88, 1·31 <0·001
RSS MAP n 24 n 24
Baseline 0·59a 0·43, 0·82 0·54a 0·39, 0·74
Week 4 0·60 0·44, 0·83 0·24* 0·17, 0·34 <0·001
Urinary P output (mg/kg BW) n 24 n 24
Baseline 39·40a 34·42, 45·10 37·58a 32·83, 43·02
Week 4 43·35 37·87, 49·63 399·21* 348·76, 456·97 <0·001
Urinary Ca output (mg/kg BW) n 24 n 24
Baseline 1·21a 0·95, 1·53 1·14a 0·89, 1·44
Week 4 1·17 0·92, 1·49 1·25 0·98, 1·59 0·868
FEP (%) n 24 n 24
Baseline 10·40a 9·03, 11·99 11·02a 9·56, 12·70
Week 4 12·50* 10·84, 14·41 183·05* 158·79, 211·02 <0·001
FECa (%) n 24 n 24
Baseline 0·13a 0·11, 0·17 0·14a 0·11, 0·18
Week 4 0·14 0·11, 0·18 0·18* 0·14, 0·23 0·236
RSS CaOx, urine relative supersaturation for calcium oxalate; RSS MAP, urine relative supersaturation for magnesium ammonium phosphate (struvite); FE, fractional excretion of
P or Ca.
a,b Mean values within a row with unlike superscript letters were significantly different between test and control at baseline (P<0·05).
* A significant difference from baseline within group (P<0·05). P-value provides a comparison of the change from baseline at week 4, between test and control diet groups.
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Fractional excretion. Calculated FEP was not significantly dif-
ferent between groups at baseline (Table 3), but after 4 weeks
of feeding increased significantly (P< 0·001) in the test group
from 11·02 (9·56, 12·71) to 183·05 (158·79, 211·02)% and this
change was significantly (P< 0·001) different from that in the
control group (Table 3). Change in FECa from baseline over the
feeding period was not significantly different between groups
(P= 0·550), even though that of the test group did increased
significantly (P= 0·039) by 1·23 (1·01, 1·50)-fold (Table 3).
Abdominal ultrasound and whole-body radiographs. A total
of twenty-two cats (92%) in the test group had changes in
echogenicity indicative of altered renal morphology. Of these,
three had subtle, seven narrow and seven broad renal cortical
rim sign (RS) identified, whereas five had a broad renal cortical
RS with parenchymal speckling and generalised increased
echogenicity. In all, two test cats (8%) had developed renoliths
and one pyelctasia. In contrast, one cat in the control group was
observed to have developed a narrow renal cortical RS.
Examination of the whole-body radiographs did not indicate any
evidence of mineralisation of soft tissues or skeletal changes.
Study 2
In all, three cats in the control group were removed from trial
after the baseline sample owing to behavioural unsuitability for
sample collection. Data from these cats are not included in the
analysis. In all, four cats were removed from the study before
28 weeks; one in the control group was removed in week 19 for
behavioural reasons and its data were not included after this
time. In all, three test group cats were removed after the 21-week
sample point revealed changes in serum biochemistry (creatinine
and urea outside of normal range) consistent with an adverse
effect on renal function and their data were included up to and
including week 21. For behavioural reasons, occasional missed
or partial samples occurred for other measures and sample
numbers are presented in the relevant figures and tables.
Intake and body weight. No significant between-group differ-
ences in BW were observed with mean values at baseline of 4·26
(3·88, 4·64) and 4·52 (4·15, 4·89) kg for the control and test groups,
respectively, and 4·27 (3·89, 4·66) and 4·49 (4·12, 4·86) kg at
week 29 (online Supplementary Table S5). No significant
(P> 0·05) between-group differences in the change in energy
intake were determined at any time (online Supplementary Table
S5). After baseline, a significant increase (P<0·001) in mean
P intake to 0·16 (0·15, 0·17) g/kg was observed in the test group
compared with the control, which did not change from a baseline
level of 0·06 (0·05, 0·07) g/kg (online Supplementary Table S5).
Mean Ca intake was also observed to increase significantly
(P<0·001) from baseline in the test group to a mean of 0·15 (0·14,
0·16) g/kg at week 28 from 0·07 (0·06, 0·08) g/kg.
Mineral apparent digestibility and balance. Urinary and
faecal P excretion in the test group increased significantly
(P< 0·001) from baseline and in comparison with the control
group (Fig. 6(a)). The change from baseline in urinary Ca
excretion was only significantly (P= 0·036) different between
groups at week 28 (Fig. 6(b)). Faecal Ca excretion increased
significantly (P< 0·001) in the test group compared with base-
line and the control group. Apparent P digestibility at baseline
was not significantly different (P= 0·996) between the control
and test groups: 38·26 (32·14, 44·38) and 40·26 (34·27, 46·25)%,
repectively. However, over the 29-week feeding period P
apparent digestibility increased in both groups to 50·36 (43·8,
56·92)% in the control group and 51·53 (44·8, 58·25)% in the
test group, and therefore no significant (P< 0·05) difference
between diet difference in change from baseline was observed.
Apparent Ca digestibility did not change significantly (P< 0·05)
from baseline (14·33 (5·52, 23·13)%) in the test group. How-
ever, in the control group Ca retention increased significantly
(P< 0·001) from baseline by 23·05 (9·94, 36·15) to 37·37(27·93,
46·81)% at week 28, a change significantly (P= 0·015) greater
than in the test group.
Total P balance was not significantly different between the
diet groups at baseline (P= 0·998) (Fig. 6(c)). From week 4 of
the feeding period, total P balance increased significantly
(P< 0·001) in the test group from 0·39 (0·18, 0·59) to 0·74 (0·52,
0·96) g/d at week 28, whereas that of the control group was
significantly (P= 0·047) higher than baseline only at the final
time point (Fig. 6(c)). Total Ca balance change from baseline
was not significantly different between the diet groups at any
time point (Fig. 6(d)).
Glomerular filtration rate. In both diet groups, no significant
(P> 0·05) change from baseline was observed and no sig-
nificant between-diet difference determined (Fig. 7).
Blood biochemistry. After 13 weeks of feeding, serum creati-
nine levels in the control group had fallen significantly
(P< 0·001) and remained lower than at baseline for the rest of
the feeding period. However, in the test group creatinine
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Fig. 5. Study 1, urine albumin creatinine ratio (UACR, mg/g) by week and diet.
Individual cat data are shown as small symbols and means as large symbols
with 95% CI, n 24. * Significant between-diet difference in change from
baseline (P< 0·05). , Control; , test.
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concentration did not change from baseline at any point (Fig. 8(a)).
A significant (P< 0·05) difference in change from baseline was
observed between groups at weeks 13 and 21 (Fig. 8(a)), but
not at week 28 (P= 0·064) (Fig. 8(a)). Of the three cats that
developed kidney disease, one was removed after serum
creatinine levels were observed to increase from 190 to
283 µmol/l between weeks 13 and 21. The other two individuals
were observed to have serum creatinine levels of 192 and
186 µmol/l at week 21 and were removed before week 28. Over
the feeding period, serum urea levels fell significantly
(P< 0·001) below baseline in the control group from 13 weeks
onwards (Fig. 8(b)), whereas those in the test group remained
unchanged (P> 0·05). A significant between-group difference
in change in serum urea (P< 0·05) was observed at weeks 21
and 28 (Fig. 8(b)). The three cats that developed kidney dis-
ease were observed to have serum urea levels of 12·1, 9·5 and
9·0mmol/l at week 21. In both diet groups serum albumin
levels decreased significantly (P< 0·001) from baseline,
although no significant (P< 0·05) between-group difference in
was observed (Table 4). Conversely, serum globulin levels
increased significantly (P< 0·001) from baseline in both
groups; no significant between diet differences in change from
baseline were detected (Table 4). Serum levels of SDMA did
not change from baseline in either diet group over the course
of the study and no between-group differences were observed
(Table 4). However, fifteen cats in the control group were
observed to have SDMA levels of between 0·75 and 1·09 μmol/l
(15 and 22 μg/dl) at one or more time point, whereas seventeen
test cats were determined to have levels between 0·74 and
1·14 μmol/l (15 and 23 μg/dl) at least once. The three cats
that developed kidney disease were observed to have SDMA
levels of 1·14, 0·84 and 0·74 μmol/l (23, 17 and 15 μg/dl) at
week 21. Serum inorganic P concentrations decreased sig-
nificantly (P< 0·001) from a baseline mean of 1·42 (1·34, 1·52)
to 1·22 (1·14, 1·3)mmol/l at week 28, whereas those of the
control group did not change (Fig. 8(c)). The change in serum
inorganic P concentration was therefore significantly different
(P< 0·01) in the test group compared with the control group
from week 13 onwards (Fig. 8(c)). Serum levels of Ca fell
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Fig. 7. Study 2, glomerular filtration rate (GFR, ml/min per kg) by study week
and diet. Individual cat data are shown as small symbols and means are shown
as large symbols with 95% CI, n 22–25. No significant between diet difference
in relative to baseline (P< 0·05) was observed. , Control; , test.
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Fig. 6. Study 2, (a) daily faecal and urinary phosphorus excretion (g/kg), n 22–24, (b) daily faecal and urinary calcium excretion (g/kg), n 22–24, (c) phosphorus
balance (g), n 22–24, (d) calcium balance (g), n 22–24, by study week and by diet. Individual cat data are shown as small symbols and means as large symbols with
95% CI. * Significant between-diet difference in change from baseline (P< 0·05). Total mineral balance (g) calculated as intake– (faecal excretion + urinary excretion).
(a, b) , Urinary – control; , urinary – test; , faecal – control; , faecal – test. (c, d) , Control; , test. BW, body weight.
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significantly (P< 0·05) from baseline in both groups, but a
significant between diet difference was only observed at week
28 (P= 0·002, Fig. 8(d)). Post-baseline changes in serum cho-
lesterol levels were observed in both groups, with significant
(P< 0·05) between-group differences detected between weeks
8 and 21 (online Supplementary Table S6). ALP concentrations
were observed to have increased (P= 0·009) from baseline in
the test group at week 13, and this change was significantly
different (P= 0·003) from that in the control group at this time
and at week 21 (online Supplementary Table S6). A transient
difference (P=0·006) in change from baseline was detected in
serum K and Na:K ratio at week 13, but no other significant
between-diet differences were observed in the biochemical
parameters measured (online Supplementary Table S6). Plasma
CaP product was not significantly different between groups at
baseline (Table 4); however, over the feeding period this
reduced significantly (P< 0·001) in the test group from 3·6 (3·3,
3·9) mmol2/l2 at baseline to 2·9 (2·7, 3·10) mmol2/l2 at week 28
and this change was significantly (P< 0·001) different from the
control group (Table 4). Additional blood biochemistry values
can be seen in online Supplementary Table S6.
Vitamin D metabolites. Serum total 25(OH)D concentrations
in the test group fell significantly (P< 0·05) from a baseline
concentration of 137·89 (117·21, 162·22) to 123·58 (104·85,
145·66) nmol/l at week 28 (Table 4). However, this change was
not significantly (P>0·05) different from that of the control group
(Table 4). Total 24,25(OH)2D serum concentration increased sig-
nificantly (P<0·05) from baseline in the test group from 24·52
(19·43, 30·95) to 30·87 (24·36, 39·12)nmol/l at week 28, and this
change was significantly (P< 0·05) different from the control
group from week 13 (Table 4). Serum levels of C3-Epi-25(OH)D3
fell significantly from baseline in the test group from week 13
(P<0·05), although this change was not significantly different
(P<0·05) from that in the control group at any point (Table 4). In
the test group, other than a transient reduction (P=0·012) in
week 4, serum levels of 1,25(OH)2D did not change from baseline
over the feeding period (Table 4). In the control group, serum
levels of 1,25(OH)2D were significantly lower than at baseline at
weeks 13 and 28 and this change was significantly different
(P<0·05) from that in the test group (Table 4).
Regulatory hormones and markers of bone turnover. Over
the feeding period, serum levels of FGF23 in the test group
increased from baseline by up to 2·91 (1·92, 4·42)-fold and this
change was significantly (P< 0·05) different from that in the
control group at weeks 2, 4, 13 and 21 (Fig. 9(a)). Serum levels
of PTH increased above baseline in the test group, although
when compared with the control this change did not reach the
level of statistical significance at time points other than weeks
21 and 28 (Fig. 9(b)). No significant between-diet differences in
change from baseline were observed in the serum levels of CTx,
although those of the control group fell significantly (P< 0·05)
(Table 4). No sustained change in BAP levels were determined in
the test group, although levels reduced significantly (P< 0·05)
compared with baseline from week 8 onwards in the control
group and this change was significantly different (P< 0·05) to
that of the test group from week 4 (Table 4).
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Table 4. Study 2 selected blood biochemistry, markers of bone metabolism and vitamin D metabolites
(Mean values and 95% confidence intervals)
Control Test
Mean 95% CI Mean 95% CI P
Albumin (g/l) n 22 n 25
Baseline 34·61a 33·43, 35·78 34·01a 32·89, 35·14
Week 2 32·60* 31·43, 33·77 31·85* 30·73, 32·98 1·000
Week 4 32·15* 30·97, 33·32 31·14* 30·01, 32·26 0·982
Week 8 31·59* 30·41, 32·77 30·34* 29·21, 31·46 0·727
Week 13 31·05* 29·87, 32·23 30·48* 29·36, 31·61 1·000
Week 21 30·96* 29·78, 32·14 29·82* 28·70, 30·95 0·896
Week 28 31·42* 30·24, 32·60 30·15* 29·00, 31·30 0·714
Globulin (g/l) n 22 n 25
Baseline 31·99a 30·02, 33·95 33·10a 31·22, 34·99
Week 2 34·89* 32·92, 36·85 35·15* 33·27, 37·03 0·931
Week 4 33·27 31·31, 35·24 33·78 31·90, 35·66 0·995
Week 8 34·23* 32·25, 36·21 34·39 32·51, 36·27 0·869
Week 13 36·72* 34·75, 38·70 36·58* 34·69, 38·46 0·567
Week 21 36·97* 35·00, 38·95 37·84* 35·96, 39·73 1·000
Week 28 36·34* 34·36, 38·31 37·38* 35·46, 39·30 1·000
SDMA (µmol/l) n 22 n 25
Baseline 0·64a 0·56, 0·71 0·65a 0·58, 0·73
Week 2 0·65 0·57, 0·72 0·66 0·59, 0·73 1·000
Week 4 0·66 0·58, 0·73 0·62 0·55, 0·69 0·764
Week 8 0·62 0·54, 0·70 0·61 0·54, 0·68 0·998
Week 13 0·60 0·52, 0·67 0·61 0·54, 0·68 1·000
Week 21 0·61 0·53, 0·68 0·63 0·56, 0·70 1·000
Week 28 0·71 0·64, 0·79 0·63 0·55, 0·70 0·077
ALP (µkat/l) n 22 n 25
Baseline 0·40a 0·33, 0·49 0·40a 0·33, 0·49
Week 2 0·41 0·33, 0·50 0·45 0·37, 0·55 0·725
Week 4 0·40 0·32, 0·49 0·44 0·36, 0·54 0·497
Week 8 0·37 0·30, 0·46 0·43 0·36, 0·53 0·123
Week 13 0·37 0·30, 0·46 0·46* 0·38, 0·56 0·003
Week 21 0·36 0·29, 0·45 0·45 0·37, 0·55 0·003
Week 28 0·38 0·31, 0·47 0·43 0·35, 0·52 0·430
CaP (mmol2/l2) n 22 n 25
Baseline 3·66a 3·39, 3·96 3·60a 3·34, 3·87
Week 2 3·38* 3·13, 3·66 3·12* 2·90, 3·36 0·572
Week 4 3·44 3·11, 3·72 3·13* 2·90, 3·37 0·295
Week 8 3·27* 3·02, 3·54 2·92* 2·72, 3·15 0·118
Week 13 3·40 3·14, 3·68 2·86* 2·65, 3·08 <0·001
Week 21 3·42 3·16, 3·70 2·93* 2·72, 3·15 0·003
Week 28 3·54 3·28, 3·83 2·92* 2·70, 3·15 <0·001
Ionised Ca (mmol/l) n 20–22 n 17–25
Baseline 1·27 1·25, 1·30 1·27 1·25, 1·29
Week 2 1·29 1·26, 1·31 1·28 1·26, 1·30 0·999
Week 4 1·28 1·26, 1·30 1·29 1·26, 1·31 0·988
Week 8 1·30* 1·28, 1·32 1·29* 1·27, 1·31 0·996
Week 13 1·30* 1·28, 1·32 1·28 1·26, 1·30 0·581
Week 21 1·30* 1·28, 1·33 1·30* 1·28, 1·32 1·000
Week 28 1·31* 1·29, 1·33 1·27 1·25, 1·30 0·003
BAP (U/l) n 21–22 n 22–25
Baseline 6·19a 4·53, 8·44 6·74a 5·00, 9·07
Week 2 6·08 4·46, 8·30 6·93 5·15, 9·33 0·998
Week 4 5·85 4·29, 7·98 7·86* 5·84, 10·60 0·003
Week 8 5·46* 4·00, 7·45 7·41 5·50, 9·98 0·002
Week 13 4·18* 3·06, 5·70 6·91 5·13, 9·30 <0·001
Week 21 4·94* 3·62, 6·74 7·63* 5·66, 10·30 <0·001
Week 29 4·73* 3·47, 6·46 6·29 4·66, 8·48 0·008
CTx (ng/ml) n 21–22 n 22–25
Baseline 0·55a 0·40, 0·74 0·51a 0·38, 0·69
Week 2 0·55 0·40, 0·74 0·51 0·39, 0·69 1·000
Week 4 0·52 0·38, 0·71 0·52 0·39, 0·69 0·988
Week 8 0·47* 0·35, 0·63 0·52 0·39, 0·70 0·157
Week 13 0·39* 0·29, 0·53 0·52 0·39, 0·70 <0·001
Week 21 0·37* 0·27, 0·50 0·45 0·339, 0·61 0·002
Week 29 0·37* 0·27, 0·50 0·42* 0·31, 0·57 0·055
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Haematology. Other than transient changes in granulocyte
numbers, no significant between diet differences were
observed in any of the haematological parameters measured
(online Supplementary Table S7).
Urinalysis. No significant between-group differences in change
in urine volume, specific gravity or urine pH was observed
(Table 5). Urinary creatinine levels did not change from base-
line in either group until week 28 when a reduction of 2·43
(2·16, 2·72)mmol/l was observed in the control group (Table 5).
Urinary microalbumin levels in the test group increased significantly
(P<0·001) from 8·14 (5·49, 12·07) to 48·15 (32·08, 72·26)mg/l,
although no change was observed in the control group
(Table 5). Consequently, UACR in the test group was observed
to increase (P< 0·001) from 2·37 (1·46, 3·84) to 14·38 (8·54,
24·21)mg/g at week 28, a change significantly (P< 0·001) dif-
ferent from that in the control (Fig. 10). Changes from baseline
in urinary Ca, citrate and sulphate were not significantly dif-
ferent between groups at any time point (Table 5). Changes in
urinary Mg, Na, urate and ammonium concentrations were
small, but at some time points were significantly (P< 0·05)
different between groups (Table 5). Urinary oxalate con-
centrations were higher in the test group than in the control by
up to 0·64 (0·17, 1·12)mmol/l (Table 5) and the change from
baseline in the test group was significantly (P< 0·05) different
from that of the control. However, changes in urinary RSS for
CaOx and struvite were not significantly different between
groups (Table 5). In contrast, brushite urinary RSS increased
significantly (P< 0·05) from baseline in the test group, and this
change was significantly different (P< 0·001) from the control at
week 12 (Table 5).
Table 4. Continued
Control Test
Mean 95% CI Mean 95% CI P
Total 25(OH)D (nmol/l) n 22 n 22–25
Baseline 129·52a 108·92, 154·01 137·89a 117·21, 162·22
Week 4 133·73 112·46, 159·02 125·95* 107·06, 148·17 0·071
Week 13 132·50 111·43, 157·55 125·59* 106·76, 147·75 0·101
Week 28 118·19 99·39, 140·54 123·58* 104·86, 145·65 1·000
Total 24,25(OH)2D (nmol/l) n 22 n 22–25
Baseline 26·78a 20·89, 34·33 24·52a 19·43, 30·96
Week 4 22·70* 17·71, 29·10 25·25 20·00, 31·88 0·133
Week 13 24·67 19·25, 31·63 29·19* 23·12, 36·85 0·017
Week 28 24·28 18·94, 31·12 30·87* 24·36, 39·13 0·001
C3-Epi-25(OH)D3 (nmol/l) n 22 n 22–25
Baseline 25·32a 21·50, 29·82 27·45a 23·55, 32·00
Week 4 26·55 22·55, 31·27 24·15 20·72, 28·16 0·318
Week 13 26·02 22·10, 30·64 22·99* 19·72, 26·80 0·169
Week 28 21·10* 17·91, 24·84 22·24* 18·93, 26·12 1·000
1,25(OH)2D (pmol/l) n 22 n 22–25
Baseline 26·28a 20·18, 34·23 29·01a 22·67, 37·11
Week 4 26·05 19·99, 33·95 24·28* 18·96, 31·11 0·106
Week 13 21·20* 16·23, 27·67 29·01 22·66, 37·12 0·040
Week 28 18·30* 14·01, 23·92 27·54 21·43, 35·38 0·004
SDMA, symmetric dimethylarginine; ALP, alkaline phosphatase; CaP, serum Ca–P product; BAP, bone-specific alkaline phosphatase; CTx, serum cross laps; 25(OH)D,
25-hydroxyvitamin D; 24,25(OH)2D, 24,25-dihydroxyvitamin D; 1,25(OH)2D, 1,25-dihydroxyvitamin D.
a Mean values within a row with unlike superscript letters were significantly different between test and control at baseline (P<0·05).
* A significant difference from baseline within group (P<0·05). P-value provides a comparison of the change from baseline at week 4, between test and control diet groups.
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Table 5. Study 2 urine analysis
(Mean values and 95% confidence intervals)
Control Test
Mean 95% CI Mean 95% CI P
Daily total urine vol. (ml) n 20–22 n 17–25
Baseline 39·67a 30·46, 51·66 32·57a 25·28, 41·96
Week 4 38·82 29·73, 50·67 28·41 21·95, 36·78 0·944
Week 12 36·26 27·77, 47·36 28·98 22·44, 37·43 1·000
Week 20 33·00 25·12, 43·33 29·64 22·77, 38·58 0·990
Week 28 33·81 25·74, 44·40 24·89* 19·01, 32·60 0·969
Urine pH n 21–22 n 21–25
Baseline 6·41a 6·16, 6·67 6·26a 6·02, 6·50
Week 4 6·38 6·12, 6·64 6·34 6·09, 6·59 0·995
Week 12 6·32 6·06, 6·58 6·44 6·19, 6·69 0·567
Week 20 6·35 6·09, 6·62 6·46 6·21, 6·71 0·635
Week 28 6·41 6·15, 6·67 6·59 6·33, 6·85 0·352
Microalbumin (mg/l) n 21–22 n 21–25
Baseline 7·17a 4·75, 10·82 8·14a 5·49, 12·07
Week 4 8·33 5·47, 12·71 101·71* 67·67, 152·88 <0·001
Week 12 6·79 4·49, 10·27 44·53* 29·92, 66·26 <0·001
Week 20 6·37 4·20, 9·65 40·54* 27·27, 60·25 <0·001
Week 28 8·23 5·42, 12·51 48·15* 32·09, 72·25 <0·001
Creatinine (mmol/l) n 21–22 n 23–25
Baseline 28·10a 24·50, 32·10 30·40a 26·70, 34·60
Week 4 28·40 24·70, 32·60 31·70 27·80, 36·20 0·991
Week 12 26·40 23·10, 30·30 31·00 27·20, 35·30 0·331
Week 20 27·70 24·20, 31·80 31·00 27·20, 35·30 0·991
Week 28 25·60* 22·40, 29·40 30·30 26·60, 34·60 0·253
Specific gravity n 20–22 n 20–25
Baseline 1·05a 1·04, 1·05 1·05a 1·04, 1·06
Week 4 1·04 1·04, 1·05 1·05 1·05, 1·06 0·786
Week 12 1·05 1·04, 1·05 1·05 1·04, 1·05 0·998
Week 20 1·04 1·04, 1·05 1·05 1·04, 1·06 1·000
Week 28 1·04 1·04, 1·05 1·05 1·04, 1·05 1·000
RS CaOx n 18–22 n 15–25
Baseline 3·48a 2·63, 4·60 4·04a 3·09, 5·29
Week 4 2·79 2·10, 3·71 2·31* 1·72, 3·12 0·152
Week 12 2·67 2·00, 3·57 3·24 2·43, 4·30 1·000
Week 20 3·95 2·95, 5·29 3·49 2·59, 4·71 0·409
Week 28 4·31 3·22, 5·78 3·20 2·33, 4·39 0·028
RSS MAP n 18–22 n 15–25
Baseline 0·86a 0·56, 1·32 1·11a 0·73, 1·68
Week 4 0·87 0·56, 1·34 1·15 0·74, 1·78 1·000
Week 12 0·84 0·539, 1·3 1·32 0·86, 2·03 0·885
Week 20 1·24* 0·79, 1·93 2·03* 1·31, 3·17 0·786
Week 28 0·93 0·60, 1·44 1·61 1·02, 2·55 0·610
Oxalate (mmol/l) n 18–22 n 15–25
Baseline 1·99a 1·68, 2·30 2·10a 1·80, 2·40
Week 4 2·08 1·77, 2·40 2·64* 2·34, 2·95 <0·001
Week 12 2·08 1·77, 2·40 2·57* 2·27, 2·87 0·004
Week 20 2·23* 1·91, 2·55 2·79* 2·48, 3·10 0·001
Week 28 2·16 1·84, 2·48 2·80* 2·49, 3·12 <0·001
RSS BRU n 18–22 n 15–25
Baseline 0·55a 0·39, 0·76 0·74a 0·53, 1·01
Week 4 0·42 0·30, 0·59 0·81 0·57, 1·15 0·151
Week 12 0·40* 0·28, 0·56 1·15* 0·82, 1·60 <0·001
Week 20 0·63 0·45, 0·89 1·29* 0·91, 1·83 0·065
Week 28 0·63 0·45, 0·89 1·07* 0·74, 1·55 0·730
Urinary Ca (mmol/l) n 20–22 n 19–25
Baseline 0·74a 0·54, 1·02 0·92a 0·68, 1·25
Week 4 0·61 0·44, 0·84 0·67* 0·49, 0·91 0·969
Week 12 0·57 0·41, 0·78 0·82 0·60, 1·11 0·922
Week 20 0·89 0·64, 1·24 0·93 0·68, 1·28 0·857
Week 28 0·99* 0·71, 1·37 0·87 0·63, 1·20 0·122
FEP (%) n 19–22 n 17–25
Baseline 20·53a 17·85, 23·61 23·34a 20·41, 26·69
Week 4 21·50 18·66, 24·78 75·22* 65·18, 86·80 <0·001
Week 12 21·30 18·48, 24·55 83·07* 72·31, 95·43 <0·001
Week 20 19·13 16·47, 22·22 75·14* 64·95, 86·94 <0·001
Week 28 20·04 17·25, 23·27 75·13* 64·38, 87·67 <0·001
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Fractional excretion. Calculated FEP was not significantly
different between groups at baseline, but after 4 weeks of
feeding had increased significantly (P< 0·001) in the test group
from 23·34 (95% CI 20·41, 26·69) to 75·22 (95% CI 65·18,
86·80)% (Table 5). This increase was sustained for the rest of
the feeding period and was significantly different (P< 0·001)
from that in the control group (Table 4). FECa was not sig-
nificantly different between groups and did not change sig-
nificantly in either group over the feeding period (Table 5).
Abdominal ultrasound, whole-body radiographs and
post-mortem histology. At the end of the study, ultrasound
examination revealed that fifteen cats (60%) in the test group
had developed renoliths compared with six cases in the control
group (27%). Evidence of changes in kidney echogenicity
indicative of structural changes were not observed in the con-
trol group, but were observed in nine test cats (36%). Of these,
one test cat was observed to have developed narrow and four
broad renal cortical RS, whereas three were observed to have
parenchymal speckling, hyperechoic medullary radiating linear
echoes or generalised increased echogenicity. In all, five test cats
(20%) were identified as having both changes in echogenicity
with renoliths present, two of which had also developed
pyelectasia. Examination of the whole-body radiographs did not
indicate evidence of any soft tissue mineralisation outside of the
kidney or skeletal changes.
Histology. In week 27, following a pre-defined clinical man-
agement pathway, one cat from the test group was euthanised
after developing acute azotaemia that did not respond to
treatment. Post-mortem and histological investigations were
carried out. Macroscopically the kidney surface was observed to
be irregular and within the cortex several white radial stripes
were observed with chronic inflammation and fibrosis. Lesions
were radially distributed supporting the presence of renal
infarcts. Inflammatory cells, multifocal flattening of the tubule
epithelial lining, accumulation of necrotic debris, dystrophic
calcifications and crystals were observed under microscopic
examination. The inflammatory infiltrate was noted to extend
into the medulla, pelvis and renal capsule. Von Kossa staining
gave a positive signal in the foci of tubular necrosis, although
negative intratubular crystals were also observed.
Discussion
In study 1, feeding cats an extruded diet with a total P content of
4·8 g/1000 kcal (4184 kJ) and Ca:P of 0·6 led to a series of
adverse health effects within 4 weeks, including reduced
appetite, increased incidence of vomiting, weight loss and changes
in renal echogenicity indicative of structural abnormalities. In
agreement with findings of Pastoor et al.(7) and Dobenecker
et al.(8), elevated serum creatinine concentrations were observed
and these were accompanied by a reduced GFR. A persistent
reduction in GFR generally indicates direct damage to the renal
tubular cells leading to loss of functioning nephrons(29). If the
initial damage is to the tubular cells(29), the cells may desquamate
into the tubular lumen causing obstruction and back flow of
filtrate into the peritubular interstitium, thus increasing glo-
merular pressure and decreasing GFR(30). In turn this leads to a
reduction in creatinine and urea clearance from the blood and
serum levels increase as observed in study 1. A significant
reduction in serum albumin levels was also observed in the test
group, possibly indicating impairment in the kidney’s ability to
retain this protein. However, as only a relatively small corre-
sponding increase in urine microablumin was observed, this may
have been because of losses due to blood sampling, as well as
reduced production due to decreased food intake. Haematolo-
gical changes observed in the study 1 test group were similar to
those reported in cats suffering from hyperthyroidism(31) – for
Table 5. Continued
Control Test
Mean 95% CI Mean 95% CI P
FECa (%) n 19–22 n 18–25
Baseline 0·15a 0·11, 0·22 0·17a 0·12, 0·24
Week 4 0·12 0·09, 0·18 0·12* 0·09, 0·18 0·986
Week 12 0·12 0·08, 0·17 0·16 0·11, 0·23 0·903
Week 20 0·17 0·12, 0·25 0·18 0·13, 0·26 0·999
Week 28 0·20 0·14, 0·29 0·17 0·12, 0·24 0·322
RSS CaOx, urine relative supersaturation for calcium oxalate; RSS MAP, urine relative supersaturation for magnesium ammonium phosphate (struvite); RSS BRU, urinary RSS for
brushite (CaHPO4.2H2O); FE, fractional excretion of P or Ca; CI, CI.
a Mean values within a row with unlike superscript letters were significantly different between test and control at baseline (P<0·05).
* A significant difference from baseline within group (P<0·05). P-value provides a comparison of the change from baseline at week 4, between test and control diet groups.
60
40
20
0
0 4
Time (weeks)
12
*
* *
*
20 28
UA
CR
 (m
g/g
)
Fig. 10. Study 2, urinary albumin creatinine ratio (UACR, mg/g) by study week
and diet. Individual cat data are shown as small symbols and means are shown
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example, erythrocyte poikilocytosis indicated by changes in
mean corpuscular volume, mean corpuscular Hb, reduced ery-
throcyte distribution width and mean platelet volume. These
changes may have been because of haemodynamic disturbance
due to reduced GFR(32). The observed alterations to serum and
urinary biochemistry are indicative of stage 2 kidney disease
classified using the International Renal Interest Society scale(33)
and are supported by the changes in renal morphology identified
by ultrasonography. Subsequent monitoring has indicated that
these changes are persistent, but not progressive.
Subsequently, study 2 was undertaken with the aim of
determining a NOAEL for dietary P. In this study, clinically
relevant changes in markers of kidney function were not
apparent in the majority of cats offered a test diet containing
3·6 g/1000 kcal (4184 kJ) of P and a Ca:P of 0·9. The mean GFR
and circulating concentrations of serum creatinine, urea and
SDMA did not change in the test group over the course of the
feeding period. It is also of note that serum levels of creatinine
and urea fell in the control group, possibly owing to differences
between the control diet and the standard diets the cats were
habituated to before the study, although it might be expected that
adaptation would have taken place over a shorter time period. P
regulatory factors, FGF23, PTH, iCa and vitamin D remained
within published normal ranges in all but three cats throughout the
second study(20,34,35). However, in common with the first study,
FGF23 and PTH levels increased significantly in response to the
increased P intake, although the changes were less marked. Not-
withstanding the lesser degree of adaptive changes observed in
study 2 and the stability of mean GFR, the incidence of kidney
stones and renal structural changes, as determined by ultrasound,
were observed to be higher in the test group. In addition, three
cats developed signs of renal dysfunction towards the end of the
feeding period, with clinically relevant changes from week 21 of
feeding. Taking these observations together, it was not possible to
establish a NOAEL for dietary P.
The bioavailability of dietary P is not only influenced by the
P content of the diet, but the ratio of Ca:P and source of P have
also been demonstrated to play important roles in absorp-
tion(9–11). Here, in study 1, extra Ca in both organic (bone and
meal meal) and inorganic (calcium carbonate) forms was added
to balance the P content of the test diets at the desired ratio.
Dietary P provided by organic raw materials (e.g. bone meal,
poultry meal or P bound by phytates) is less bioavailable than
that arising from added inorganic sources (e.g. P containing
mono and dibasic Na salts)(7,12). Phosphates are widely used in
commercial human and pet food manufacturing, where they
serve a number of processing functions and as a source of
required dietary P(13). Such P salts easily disassociate, solubilise
and are readily absorbed in the intestinal tract; hence, P
absorption can be greatly influenced by the chemical form
ingested, with both circulating P concentration and urinary P
excretion influenced by differences in dietary P availability(12).
Evidence suggests that over 90% of inorganic P may be bioa-
vailable, compared with between 40 and 60% for naturally
occurring sources(10); the proportion of dietary P coming from
inorganic sources probably contributed to the effects seen after
consumption of high P diets in the present studies, as well as
those reported by Pastoor et al.(7) and Dobenecker et al.(8). The
test diets used here were formulated using relatively high levels
of inorganic SDHP, which has been reported to be highly
bioavailable and to have a greater effect on renal parameters
than calcium monophosphate(36). Inorganic neutral monobasic/
dibasic sodium phosphates have been observed to increase
urinary P concentration more than those originating from
organic dietary P sources(12), and the higher level of dietary Na
associated with these salts may stimulate of Na+-dependent
uptake of phosphate(14). This action could have exacerbated
the adverse effects of P intake in the studies presented here and
particularly in study 2 when total P level was moderate. How-
ever, it is unlikely that Na levels alone induced the renal
changes observed here. A study on the effects of dietary salt
intake on renal function in healthy aged cats using a test diet at
a similar level of Na inclusion did not induce deleterious effects
on renal function or changes in plasma P, creatinine and PTH
over a 2-year feeding period(37). In a recent study of the post-
prandial effects of dietary P in cats, Coltherd et al.(38) observed
that plasma P profiles are responsive to changes in dietary P
content and that inorganic P content drives this response in a
dose-dependent manner. These authors report that feeding
diets with a high inclusion of SDHP and a Ca:P <1·0 induced a
significant increase in postprandial plasma P levels that was
sustained for 6 h. Our findings therefore support other reports
indicating that diets including high levels of P from inorganic
salts may have adverse effects on renal health in healthy
cats(12,36,39,40).
Circulating P levels are regulated by a number of hormones
including FGF23 and PTH. In both studies, when high levels of P
were ingested, levels of these hormones increased possibly in an
attempt to maintain homoeostasis. PTH and FGF23 reduce
reabsorption of phosphate in the proximal tubule, resulting in
increased P concentration in the tubule, potentially leading to
crystallisation(41). PTH acts by reducing sodium phosphate
cotransporter expression on the apical membrane of the prox-
imal tubule and induces increased urinary P excretion(42), as
observed here. FGF23 and its cofactor, klotho, bind to FGF
receptors type 1 in the proximal tubule and inhibit synthesis of
the sodium phosphate cotransporter and 1α-hydroxylase, an
enzyme involved in hydroxylation of 25(OH)D (calcifediol) to
1,25(OH)2D (calcitriol the bioactive form of vitamin D)
(43). As a
result, more P would be expected to be excreted in urine and,
owing to reduced levels of vitamin D, less P absorbed from the
intestine, hence reducing the circulating P level. In the current
studies, although urinary P concentration increased in the test
groups as might be expected, there was no reduction in P
apparent digestibility. While remaining within the normal range
(0·8–1·9mmol/l), circulating P concentrations in both studies were
observed to reduce, possibly indicating an over-compensation in
urinary excretion. In the first study, owing to the relatively low
circulating P levels compared with the high urinary excretion
observed, calculated FEP increased significantly over the feeding
period to levels much higher than those reported as normal for cats
(<73%)(44,45) and considered physiologically impossible as net
tubular secretion of phosphate does not occur. This may be
because the fasting levels of circulating P measured in the study are
not indicative of transient postprandial changes in concentration. It
has been reported in dogs that FE of a number of minerals is
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significantly higher after feeding, and postprandial measurements
may offer further information on adaptations made in response to
dietary intake(46). In the second study, while FEP increased sig-
nificantly in response to the more moderate levels of dietary P,
although still likely to be an over-estimation owing to postprandial
fluctuations in plasma P concentration, values were closer to the
reported physiological maximum. Other minerals may also exert
effects on P regulation – for example, Mg and P metabolism have
previously been linked and hypomagnesaemia has been asso-
ciated with raised FGF23 production and the progression of CKD in
cats(47). However, here dietary Mg levels, while meeting nutritional
requirements(4), were not fixed and neither serum nor faecal Mg
levels were assessed; hence, the contribution of this mineral cannot
be interrogated.
P absorption in the gut is regulated by the effect of
1,25(OH)2D on intestinal NaPi-2b transporters
(48). However, in
both studies, the expected suppression of serum 1,25(OH)2D by
FGF23 was not observed, although circulating levels of its precursor
25(OH)D did reduce significantly in the test groups. Increased PTH
owing to ingestion of significant quantities of bioavailable P could
counteract the effect of FGF23 by upregulating synthesis of 1,25-
(OH)2D in an attempt to increase Ca absorption. Although in the
first study Ca balance became negative, no significant reduction in
serum Ca or iCa was observed and FECa remained within reported
normal range(44,49). In the absence of changes in iCa, it is, however,
possible that PTH secretion could be increased owing to transient
fluctuations in postprandial extracellular P concentration(50,51).
Such postprandial changes in circulating iCa or P, although suffi-
cient to induce PTH, would not be detected in the fasted blood
samples taken in the current study. Circadian patterns of serum P,
which can be modified by intake, have been observed in humans
and it has been suggested that studies targeting intestinal phos-
phate absorption should consider afternoon phosphate measure-
ments(52). Coltherd et al.(38) have reported that feeding a diet with a
high inclusion of SDHP decreased iCa and increased PTH post-
prandially. It has also been reported that stimulation of PTH by
hypocalcaemia or hyperphosphataemia may be counteracted by
balancing dietary Ca:P(53,54). This postulated protective effect of Ca:
P is supported by Coltherd et al.(38), who observed altered iCa and
PTH response when a diets of similar SDHP concentration but
differing Ca:P was fed. PTH is also reported to increase the rate of
bone resorption(55,56), and remodelling, a recognised consequence
of increased P load(3). After ingestion of excess P, deposition of Ca
and P in bone may increase hypocalcaemia and raise markers of
bone turnover(57). In study 1, cats offered the test diet were
observed to have increased levels of ALP and BAP. ALP breaks
down pyrophosphate or β-glycerophosphate into inorganic phos-
phate essential to osteoblast differentiation and mineralisation(58)
and may also play a role in the intestinal absorption of inorganic P
to facilitate transport(57). However, such changes were not
observed in study 2, when a more moderate amount of P was
fed(59) and no skeletal mineralisation or demineralisation was
observed in radiographs from either study. Despite this, Ca balance
was observed to become negative in the first study, indicating
increased secretion of Ca into the intestine – a phenomenon pre-
viously correlated with high P intake(60). This endogenous Ca is
probably released from bone, which may be evidenced by the
raised levels of ALP owing to increased bone remodelling(61).
Increased total P burden can induce soft tissue mineralisation
in the kidneys and other organs and deleterious effects of
phosphate accumulation can be a direct consequence of cal-
cium phosphate precipitates in the tissues. However, in both
studies reported here the fasting CaP product was observed to
be well below the level at which mineralisation is reported to
occur (70mg2/dl2; 5·6 mmol2/l2)(62,63). The reduction in serum
P concentration observed in the test groups actually lowered
CaP, which would be expected to reduce the risk of miner-
alisation(63). In the urinary tract, calculi are the most common
form of mineralisation and cortical nephrocalcinosis may
appear as increased echogenicity in or around the cortex. In
both of the current studies, changes in renal echogenicity
consistent with mineralisation were observed and histological
examination of renal tissue from one cat indicated the presence
of crystals and Ca deposits. P intake in cats has previously been
reported to play a role in urolithiasis(7), and in study 2 a higher
incidence of renolith formation was observed in the test group.
P is a component of struvite (MAP) and diets with a high P
content have been associated with increased risk of struvite
stone formation(64). However, no sustained increase in urinary
struvite RSS was observed with mean levels remaining at less
than that regarded as metastable (<2.5)(65). Crystallisation
required for struvite renolith formation only occurs when
mineral concentrations are sufficiently high and the urine pH is
neutral or alkaline. Here, mean urinary pH was between 6·3
and 6·6 – in the range recommended to reduce the risk of
struvite crystal formation in cats(66). CaOx is reported as the
most common mineral found in feline renoliths(67). In the
second study, urine concentrations of oxalate were sig-
nificantly increased in the test group, although mean urinary
RSS for CaOx was similar between groups and below 10, a
level reported to reduce the risk of stone formation(65). In cats
primary hyperoxaluria has been noted to result in the presence
of birefringent crystals in the tubules and renal fibrosis; how-
ever, such cases are rare and linked to a genetic disease similar
to human primary hyperoxaluria type 2(68). In the current
study, urinary RSS for brushite (CaHPO4.2H2O), another stone-
forming mineral, was increased significantly in the test group
compared with the control group. Although brushite stones are
normally uncommon in cats(67), in humans metabolic
abnormalities such as renal tubular acidosis and primary
hyperparathyroidism are common in brushite stone disease(69).
Furthermore, humans who form brushite renoliths demonstrate
renal cellular damage(70) and kidney cell injury is associated
with the presence of brushite crystals(71). It has been proposed
that a physiological change or insult causing loss of collecting
duct cell pH regulation can trigger crystallisation resulting in
cell injury and death. In alignment with the histological
observations made in study 2, the crystallisation process in
humans was observed to enlarge the collecting duct and to
initiate interstitial inflammation(71). It is possible that in the
current studies the levels of P reaching the kidney could initiate
a similar process, with length of exposure to the P a con-
tributing factor as increased incidence of renolith formation
was only observed in study 2. However, as renoliths were also
identified in a number of control cats, the effects of other
promoters of crystal precipitation and aggregation cannot be
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excluded. While little information is available on renolith
incidence and development in the general cat population, the
development of renoliths in the control group over the feeding
period was surprising and higher than that observed in a
comparable population of colony cats (approximately 11% of
cats)(72). The incidence of renolith formation could possibly
have been influenced by the lower P content of the control diet
as a study evaluating dietary risk factors for CaOx urolithiasis
reported that cats consuming diets with lower P content had
increased risk for CaOx urolithiasis(64). However, the control
diet was at a P level similar to commercial diets designed for
senior cats and not reported to induce negative effects on renal
function(73). One shortcoming of the study is the lack of renolith
analysis to confirm chemical composition and indicate
mechanism of formation. However, surgical intervention to
remove the stones was deemed not to be in the therapeutic
interest of the cats by the attending veterinary team. It is pos-
sible that the moderate protein levels of the diets used could
have also influenced the outcome of these studies. Although the
formulations were based on standard extruded commercial pro-
ducts, protein inclusion was limited owing to the requirement to
produce diets with similar nutrient levels other than P and Ca
inclusion. Furthermore, if high-protein inclusion study diets had
been used, this could have been a confounding factor in assessment
of the impact of dietary P on renal health, as a recent retrospective
study has identified a link between high protein intakes and CKD in
cats(74). Although the test diet offered in the first study and the
control diet offered in the second study were, respectively, 1·3 and
0·4% lower than the AAFCO minimum for adult maintenance (26%
of DM)(6), all the diets used were at least 20% above the NRC (2006)
adult protein RA(4). It would therefore seem unlikely that physio-
logically meaningful protein deficiency would have occurred over
the course of these studies, although this may have resulted in lower
circulating creatinine and albumin levels. The conclusions drawn
from the studies presented here must, however, be considered in
the context of a moderate dietary protein intake.
In conclusion, the results of the present studies suggest that
4-week feeding of a diet containing 4·8 g/1000 kcal (4184 kJ)
total P, with a Ca:P of 0·6 and formulated to contain 5·2% (3·6g/
1000kcal (4184 kJ)) SDHP, causes renal dysfunction in healthy
adult cats. In addition, in most cats prolonged feeding of a diet
with a total dietary P content of 3·6g/1000kcal (4184 kJ), Ca:P 0·9,
formulated to contain 2·2% (1·5g/1000kcal (4184 kJ)) SDHP
results in no change in renal function. However, sonographic
changes to the kidneys were observed in some individuals, and
although the clinical significance of these is not known in a small
number renal dysfunction did occur. Multiple sources of evidence
suggest that dietary P provided by organic raw materials is less
bioavailable than that arising from added inorganic sources,
including the SDHP used in the present study. Furthermore, recent
studies by our group suggest that diets with a high inclusion of
inorganic P and specifically SDHP, along with a Ca:P <1·0, induce
a prolonged increase in serum concentration postprandially(38)
and that this may be an important factor in the adverse effects
observed here. As a NOAEL for dietary P was not established,
further work is required to determine both this and the effects
dietary P source and Ca:P ratio have on renal health in healthy
adult cats.
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